Abstract: Disclosed are tumor necrosis factor receptor 1B (TNFR-1B) signaling targets and TNFR-1B mutants and their uses for treatment of diseases and disorders.

Abstract: Methods and systems for high-throughput Identification of receptor: ligand interactions are provided. Throughout this application various publications are referred to in parentheses. Full citations for these references may be found at the end of the specification. The disclosures of these publications, and all patents, patent application publications and books referred to herein, are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.

Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.

Abstract: The present disclosure provides variant PD-L1 immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.

Abstract: Methods and compositions for clonally inhibiting or clonally stimulating T-cells are provided.

Abstract: Disclosed are tumor necrosis factor receptor 1B (TNFR-1B) signaling targets and TNFR-1B mutants and their uses for treatment of diseases and disorders.

Abstract: Methods and systems for high-throughput identification of receptor:ligand interactions are provided.

Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.

Abstract: Methods and systems for the efficient and systematic identification of the repertoire of T-cell epitopes.

Abstract: Methods and compositions for clonally inhibiting or clonally stimulating T-cells are provided.

Abstract: Methods and systems for high-throughput identification of receptor:ligand interactions are provided.

Abstract: Isolated polypeptides comprising a mutant programmed cell death 1 (PD-1) polypeptide and fusion polypeptides comprising an isolated mutant PD-1 polypeptide fused to an immunoglobulin domain polypeptide are provided. Further provided are methods of using a composition comprising the fusion polypeptide for stimulating T cell activation for treating disorders including a tumor or an infection.

Abstract: The present invention provides a method of determining related proteins, the method comprising obtaining sequences of interest, wherein the sequences are amino acid sequences for proteins or nucleotide sequences encoding proteins; comparing segments of each sequence of interest with a database of amino acid or nucleotide sequences; generating a profile for each sequence of interest comprising a list of all sequences from the database of sequences that have segments corresponding to the segments of each sequence of interest; and comparing the database sequences appearing in the profile of each sequence of interest to the database sequences appearing in the profile of every other sequence of interest, wherein similar profiles indicate that the sequences of interest correspond to related proteins while dissimilar profiles indicate that the sequences of interest do not correspond to related proteins, wherein profiles are similar if there is at least a 30% overlap between the database sequences appearing in the pr